Activated rho kinase mediates diabetes-induced elevation of vascular arginase activation and contributes to impaired corpora cavernosa relaxation: Possible involvement of p38 MAPK activation

Journal of Sexual Medicine

Volumn 10, Issue 6, 2013, Pages 1502-1515

  Toque, Haroldo A ^a   Nunes, Kenia P ^a   Yao, Lin ^a   Liao, James K ^b   Webb, R Clinton ^a   Caldwell, Ruth B ^a   Caldwell, R William ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Arginase; Diabetes; P38 MAPK; Rho Kinase

Indexed keywords

2 AMINO 6 BORONOHEXANOIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCHOLINE; AGENTS ACTING ON THE GENITAL SYSTEM; ARGINASE; ARGINASE 2; GLUCOSE; HEXANOIC ACID; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSIN PHOSPHATASE TARGET SUBUNIT 1; PHOSPHATASE; RHO KINASE; RHO KINASE 1; RHO KINASE 2; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS CAVERNOSUM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ERECTILE DYSFUNCTION; GENOTYPE; GLUCOSE BLOOD LEVEL; KNOCKOUT MOUSE; MALE; MOUSE; MUSCLE RELAXATION; NERVE STIMULATION; NITRERGIC NERVE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STREPTOZOCIN DIABETES; WILD TYPE;

EID: 84878736457     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12134     Document Type: Article

References (50)

1. Andersson KE. Pharmacology of penile erection. Pharmacol Rev 2001;53:417-450.
2. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005;32:379-395.
3. Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, Champion HC. Increased expression of arginase II in human diabetic corpus cavernosum: In diabetic-associated erectile dysfunction. Biochem Biophys Res Commun 2001;283:923-927.
4. Durante W, Johnson FK, Johnson RA. Arginase: A critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 2007;34:906-911.
5. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, Caldwell RB, Caldwell RW. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008;102:95-102.
6. Grönros J, Jung C, Lundberg JO, Cerrato R, Ostenson CG, Pernow J. Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am J Physiol Heart Circ Physiol 2011;300:H1174-1181.
7. Toque HA, Tostes RC, Yao L, Xu Z, Webb RC, Caldwell RB, Caldwell RW. Arginase II deletion increases corpora cavernosa relaxation in diabetic mice. J Sex Med 2011;8:722-733.
8. Zhang C, Hein TW, Wang W, Chang CI, Kuo L. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J 2001;15:1264-1266.
9. Bachetti T, Comini L, Francolini G, Bastianon D, Valetti B, Cadei M, etal. Arginase pathway in human endothelial cells in pathophysiological conditions. J Mol Cell Cardiol 2004;37:515-523.
10. Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L, etal. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: Implications for atherosclerotic endothelial dysfunction. Circulation 2004;110:3708-3714.
11. Morris SM Jr. Recent advances in arginine metabolism: Roles and regulation of the arginases. Br J Pharmacol 2009;157:922-930.
12. Chitaley K, Wingard CJ, Clinton Webb R, Branam H, Stopper VS, Lewis RW, Mills TM. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 2001;7:119-122.
13. Priviero FB, Jin LM, Ying Z, Teixeira CE, Webb RC. Up-regulation of the RhoA/Rho-kinase signaling pathway in corpus cavernosum from endothelial nitric-oxide synthase (NOS), but not neuronal NOS, null mice. J Pharmacol Exp Ther 2010;333:184-192.
14. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, Lewis RL, Mills TM, Hellstrom WJ, Kadowitz PJ. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: A mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A 2004;101:9121-9126.
15. Mills TM, Chitaley K, Wingard CJ, Lewis RW, Webb RC. Effect of Rho-kinase inhibition on vasoconstriction in the penile circulation. J Appl Physiol 2001;91:1269-1273.
16. Rees RW, Ziessen T, Ralph DJ, Kell P, Moncada S, Cellek S. Human and rabbit cavernosal smooth muscle cells express Rho-kinase. Int J Impot Res 2002;14:1-7.
17. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: Effect on endothelial NAD(P)H oxidase system. Circ Res 2003;93:767-775.
18. Shah DI, Singh M. Effect of fasudil on macrovascular disorder-induced endothelial dysfunction. Can J Physiol Pharmacol 2006;84:835-845.
19. Jin L, Liu T, Lagoda GA, Champion HC, Bivalacqua TJ, Burnett AL. Elevated RhoA/Rho-kinase activity in the aged rat penis: Mechanism for age-associated erectile dysfunction. FASEB J 2006;20:536-538.
20. Chandra S, Romero M, Shatanawi A, Caldwell R, Caldwell R. Oxidative species increase arginase activity through the RhoA/Rho kinase (RAK) pathway. Br J Pharmacol 2011;165:506-519.
21. Shatanawi A, Romero MJ, Iddings JA, Chandra S, Umapathy NS, Verin AD, Caldwell RB, Caldwell RW. Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am J Physiol Cell Physiol 2011;300:C1181-1192.
22. Horowitz S, Binion DG, Nelson VM, Kanaa Y, Javadi P, Lazarova Z, Andrekopoulos C, Kalyanaraman B, Otterson MF, Rafiee P. Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2007;292:G1323-1336.
23. Rodrigues-Díez R, Carvajal-González G, Sánchez-López E, Rodríguez-Vita J, Rodrigues Díez R, Selgas R, Ortiz A, Egido J, Mezzano S, Ruiz-Ortega M. Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharm Res 2008;25:2447-2461.
24. Behr TM, Berova M, Doe CP, Ju H, Angermann CE, Boehm J, Willette RN. p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease. Curr Opin Investig Drugs 2003;4:1059-1064.
25. Takahashi M, Okazaki H, Ogata Y, Takeuchi K, Ikeda U, Shimada K. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis 2002;161:387-394.
26. Liscovsky MV, Ranocchia RP, Gorlino CV, Alignani DO, Morón G, Maletto BA, Pistoresi-Palencia MC. Interferon-gamma priming is involved in the activation of arginase by oligodeoxinucleotides containing CpG motifs in murine macrophages. Immunology 2009;128:159-169.
27. Toque HA, Romero MJ, Tostes RC, Shatanawi A, Chandra S, Carneiro Z, Inscho E, Webb RC, Caldwell RB, Caldwell RW. p38 Mitogen-activated protein kinase (MAPK) increases arginase activity and contributes to endothelial dysfunction in corpora cavernosa from angiotensin-II treated mice. J Sex Med 2010;12:3857-3867.
28. Jin L, Lagoda G, Leite R, Webb RC, Burnett AL. NADPH oxidase activation: A mechanism of hypertension-associated erectile dysfunction. J Sex Med 2008;5:544-551.
29. Rikitake Y, Oyama N, Wang CY, Noma K, Satoh M, Kim HH, Liao JK. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation 2005;112:2959-2965.
30. Thumkeo D, Keel J, Ishizaki T, Hirose M, Nonomura K, Oshima H, Oshima M, Taketo MM, Narumiya S. Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol 2003;23:5043-5055.
31. Muranyi A, Derkach D, Erdodi F, Kiss A, Ito M, Hartshorne DJ. Phosphorylation of Thr695 and Thr850 on the myosin phosphatase target subunit: Inhibitory effects and occurrence in A7r5 cells. FEBS Lett 2005;579:6611-6615.
32. Demougeot C, Prigent-Tessier A, Marie C, Berthelot A. Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. J Hypertens 2005;5:971-978.
33. Chang S, Hypolite JA, Changolkar A, Wein AJ, Chacko S, DiSanto ME. Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta. Int J Impot Res 2003;15:53-62.
34. Buyukafsar K, Un I. Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice. Eur J Pharmacol 2003;472:235-238.
35. Chiou WF, Liu HK, Juan CW. Abnormal protein expression in the corpus cavernosum impairs erectile function in type 2 diabetes. BJU Int 2010;105:674-680.
36. Mills TM, Chitaley K, Lewis RW, Webb RC. Nitric oxide inhibits RhoA/Rho-kinase signaling to cause penile erection. Eur J Pharmacol 2002;439:173-174.
37. Rajasekaran M, White S, Baquir A, Wilkes N. Rho-kinase inhibition improves erectile function in aging male Brown-Norway rats. J Androl 2005;26:182-188.
38. Li WJ, Park K, Paick JS, Kim SW. Chronic treatment with an oral rho-kinase inhibitor restores erectile function by suppressing corporal apoptosis in diabetic rats. J Sex Med 2011;8:400-410.
39. Komers R, Oyama TT, Beard DR, Anderson S. Effects of systemic inhibition of Rho kinase on blood pressure and renal haemodynamics in diabetic rats. Br J Pharmacol 2011;162:163-174.
40. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001;22:32-39.
41. Pieper GM, Dondlinger LA. Plasma and vascular tissue arginine are decreased in diabetes: Acute arginine supplementation restores endothelium-dependent relaxation by augmenting cGMP production. J Pharmacol Exp Ther 1997;283:684-691.
42. Hagenfeldt L, Dahlquist G, Persson B. Plasma amino acids in relation to metabolic control in insulin-dependent diabetic children. Acta Paediatr Scand 1989;78:278-282.
43. Kim NN, Cox JD, Baggio RF, Emig FA, Mistry SK, Harper SL, Speicher DW, Morris SM Jr, Ash DE, Traish A, Christianson DW. Probing erectile function: S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum. Biochemistry 2001;40:2678-2688.
44. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, Kaibuchi K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 1996;271:20246-20249.
45. Kureishi Y, Kobayashi S, Amano M, Kimura K, Kanaide H, Nakano T, Kaibuchi K, Ito M. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem 1997;272:12257-12260.
46. Yao L, Chandra S, Toque HA, Bhatta A, Caldwell RC, Caldwell RW. Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho kinase knockout. Cardiovasc Res 2013;97:509-519.
47. Bao W, Behm DJ, Nerurkar SS, Ao Z, Bentley R, Mirabile RC, Johns DG, Woods TN, Doe CP, Coatney RW, Ohlstein JF, Douglas SA, Willette RN, Yue TL. Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production. J Cardiovasc Pharmacol 2007;49:362-368.
48. Kloesch B, Liszt M, Steiner G, Bröll J. Inhibitors of p38 and ERK1/2 MAPkinase and hydrogen sulphide block constitutive and IL-1β-induced IL-6 and IL-8 expression in the human chondrocyte cell line C-28/I2. Rheumatol Int 2012;32:729-736.
49. Du Y, Tang J, Li G, Berti-Mattera L, Lee CA, Bartkowski D, Gale D, Monahan J, Niesman MR, Alton G, Kern TS. Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function. Invest Ophthalmol Vis Sci 2010;51:2158-2164.
50. Nangle MR, Cotter MA, Cameron NE. Correction of nitrergic neurovascular dysfunction in diabetic mouse corpus cavernosum by p38 mitogen-activated protein kinase inhibition. Int J Impot Res 2006;18:258-263.